INSM

Insider trade Sale by Smith Michael Alexander (Chief Legal Officer)

10d ago

Insider trade Sale by Lewis William (Chair and CEO)

12d ago

News Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

14d ago

News Insmed Unusual Options Activity For July 11 - Benzinga

14d ago

News Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

14d ago

News This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

14d ago

Insider trade Sale by Adsett Roger (Chief Operating Officer)

17d ago

Insider trade Sale by Flammer Martina M.D. (Chief Medical Officer)

17d ago

Insider trade Sale by Flammer Martina M.D. (Chief Medical Officer)

17d ago

Insider trade Sale by Smith Michael Alexander (Chief Legal Officer)

17d ago

Insider trade Sale by Lewis William (Chair and CEO)

17d ago

Insider trade Sale by Bonstein Sara (Chief Financial Officer)

17d ago

Insider trade Sale by Martina Flammer M.D. (Chief Medical Officer)

19d ago

Scanner Large down move: 23.4% (2.0x normal daily movement)

24d ago

Scanner Large down move: 23.4% (2.1x normal daily movement)

25d ago

News Insmed reiterates BRINSUPRI at least $1B 2026 revenue target while targeting ARIKAYCE label expansion in H1 2027

25d ago

News Nasdaq 100 Climbs Records, Oil Extends Drop As Iran Weighs Hormuz Deal: Stock Market Today

25d ago

SEC filing INSM Reports $306M Q1 Rev, $207.9M BRINSUPRI (+44% QoQ), $98.1M ARIKAYCE (+6% YoY), Reaffirms $1B BRINSUPRI Guidance, $450-470M ARIKAYCE Guidance, ENCORE Study Meets Primary Endpoints, PALM-PAH Study Initiated, sNDA Planned H2 2026

26d ago

Insider trade Sale by William Lewis (Chair and CEO)

26d ago

News Nasdaq hits record high after Iran opens Strait of Hormuz

45d ago

Insider trade Sale by William Lewis (Chair and CEO)

45d ago

Insider trade Sale by William Lewis (Chair and CEO)

54d ago

News Insmed drops skin disorder candidate after mid-stage trial setback

55d ago

News Insmed rises on late-stage trial results for Arikayce for lung infection

70d ago

SEC filing INSM Reports Positive Phase 3b ENCORE Study Topline: 590mg ARIKAYCE + azithromycin/ethambutol 3.11 pts Resp Score Δ, 30.8% Culture Conv Δ, p<0.0001; Plans sNDA filing H2 2026, PMDA submission, Investor Call Mar 23 8 AM ET

71d ago